Learn the complete step-by-step process for reconstituting lyophilised research peptides with bacteriostatic water safely and correctly for laboratory use.

What is Peptide Reconstitution?

Reconstitution is the process of dissolving a lyophilised (freeze-dried) peptide powder into a liquid solvent to create a solution suitable for laboratory use. Research peptides are supplied in lyophilised form because this maximises stability and shelf life during storage and transport. Before use in any laboratory application, the powder must be reconstituted correctly to preserve the peptide's integrity and ensure accurate concentration calculations.

Bacteriostatic Water vs Sterile Water

The most important decision in reconstitution is solvent selection. Bacteriostatic water (BAC water) is the recommended solvent for most research peptides and is the standard across the industry. It contains 0.9% benzyl alcohol as a preservative, which prevents bacterial growth and allows the reconstituted solution to be stored at +4°C for up to 4 weeks without contamination risk.

Sterile water contains no preservative and should only be used when the reconstituted solution will be used immediately. For any laboratory situation where the vial will be accessed multiple times over days or weeks, bacteriostatic water is the correct choice.

Acetic acid solution (0.1-1%) is occasionally used for peptides that are poorly soluble in water, such as some growth hormone releasing peptides. Always consult the specific peptide's handling documentation before selecting a solvent.

Equipment Required

• Lyophilised peptide vial • Bacteriostatic water vial • Sterile insulin syringe (1ml) • Alcohol swabs • Clean work surface

Step by Step Reconstitution Process

Step 1, Preparation: Allow both the peptide vial and the bacteriostatic water to reach room temperature before beginning. Working with cold solutions can affect dissolution and may cause the peptide to clump.

Step 2, Sterilise: Wipe the rubber stopper of both vials thoroughly with an alcohol swab and allow to air dry for 30 seconds.

Step 3, Draw the solvent: Draw the required volume of bacteriostatic water into a sterile syringe. For a standard 5mg vial, 2ml of bacteriostatic water is a common starting point giving a concentration of 2.5mg/ml. Adjust according to your research protocol.

Step 4, Inject slowly: Insert the needle into the peptide vial at an angle and slowly inject the bacteriostatic water down the inner side of the glass vial wall. Do not inject directly onto the peptide powder as this can degrade the compound. Inject slowly over 10-15 seconds.

Step 5, Dissolve gently: Once all the water has been added, gently swirl the vial in a slow circular motion. Never shake a peptide vial, shaking introduces air bubbles and can break peptide bonds, degrading the compound. Allow 1-2 minutes for full dissolution. The solution should be clear and colourless.

Step 6, Store correctly: Once reconstituted, store the vial at +4°C (standard refrigerator temperature). Label the vial with the reconstitution date. Use within 4 weeks.

Calculating Concentration

Concentration (mg/ml) = Total peptide mg ÷ Volume of BAC water added in ml

Example: 5mg peptide + 2ml BAC water = 2.5mg/ml concentration

To calculate volume to draw for a specific dose: Volume (ml) = Desired dose (mg) ÷ Concentration (mg/ml)

Use the UK Peptide Lab peptide calculator for instant calculations.

Common Mistakes to Avoid

• Shaking instead of swirling, always swirl gently • Using tap water or non-sterile water, always use bacteriostatic water • Injecting directly onto the powder, always inject down the glass wall • Not labelling the vial with reconstitution date • Storing reconstituted solution in the freezer repeatedly, aliquot first if long-term storage is needed

Storage After Reconstitution

Reconstituted peptides remain stable at +4°C for up to 4 weeks. For longer term storage, draw the solution into multiple small syringes or vials (aliquots) and store at -20°C. This prevents repeated freeze-thaw cycles which degrade peptide quality over time. Never refreeze a vial that has already been thawed and partially used.

Originally published at https://ukpeptidelab.co.uk/blog/how-to-reconstitute-peptides. For in-vitro laboratory research only.

MOTS-C is a short peptide encoded within mitochondrial DNA. Discovered in 2015, it has become a central tool in research on AMPK signalling, metabolic homeostasis, and mitochondrial-nuclear crosstalk.

What is MOTS-C?

MOTS-C (Mitochondrial Open reading frame of the Twelve S rRNA-C) is a 16-amino-acid peptide encoded within the mitochondrial 12S ribosomal RNA region of human mitochondrial DNA. It was identified and characterised in 2015 by Lee and colleagues at the University of Southern California, published in Cell Metabolism. MOTS-C belongs to a small family of mitochondrial-derived peptides (MDPs) that includes Humanin, and it has rapidly become one of the most actively studied tools in research examining mitochondrial-nuclear signalling crosstalk.

Mitochondrial-Derived Peptide Discovery

Mitochondrial-derived peptides are a relatively recent area of research. Before the identification of Humanin in 2001 and MOTS-C in 2015, the mitochondrial genome was thought to encode only the 13 proteins of the electron transport chain plus the necessary rRNAs and tRNAs. The discovery of small open reading frames within the mitochondrial 16S and 12S rRNA regions that produce biologically active peptides has changed this understanding. MOTS-C is one of the best-characterised members of this peptide class.

AMPK Pathway and Metabolic Research

MOTS-C is studied primarily in the context of metabolic homeostasis and energy sensing. Published research indicates that MOTS-C activates AMP-activated protein kinase (AMPK), a key cellular energy sensor that responds to elevated AMP/ATP ratios. AMPK activation upregulates catabolic pathways such as fatty acid oxidation and glucose uptake, while downregulating anabolic pathways such as protein and lipid synthesis. MOTS-C research therefore overlaps with broader research on AMPK modulators such as metformin, AICAR, and exercise mimetics, with distinct mechanistic features.

Research Applications

MOTS-C has been studied in models of insulin sensitivity, obesity-induced metabolic dysfunction, exercise physiology, and ageing biology. The peptide has shown effects in mouse models on glucose tolerance, weight regulation under high-fat diet conditions, and exercise capacity. It has also been investigated in models of bone metabolism and immune function. Research interest has expanded to include the role of mitochondrial-derived peptides as endocrine signalling molecules with effects beyond the mitochondria of origin.

Laboratory Handling

MOTS-C is supplied as lyophilised powder. Store at -20°C prior to reconstitution. Reconstitute with bacteriostatic water by slowly injecting the diluent down the side of the vial and gently swirling. Store reconstituted solutions at 2-8°C and use within 4 weeks. Avoid repeated freeze-thaw cycles which compromise peptide integrity.

Sourcing in the UK

UK Peptide Lab supplies research-grade MOTS-C 10mg with full third-party Certificate of Analysis on every product page. Same-day UK dispatch on orders placed before 2pm GMT, free Royal Mail Tracked shipping over £45. For in-vitro laboratory research use only.

Originally published at https://ukpeptidelab.co.uk/blog/mots-c-mitochondrial-derived-peptide-research. For in-vitro laboratory research only.

PT-141 (Bremelanotide) is a cyclic heptapeptide derived from Melanotan II, modified to remove MC1R activity and concentrate action at the central MC3R and MC4R receptors.

What is PT-141?

PT-141, also known as Bremelanotide, is a synthetic cyclic heptapeptide derived from the structure of Melanotan II. It was developed by Palatin Technologies through structural modification of Melanotan II to remove the C-terminal amide responsible for MC1R binding while preserving activity at the central melanocortin receptors MC3R and MC4R. The result is a peptide with substantially reduced melanogenic effect and concentrated activity at the central nervous system melanocortin receptors involved in sexual desire and arousal signalling.

MC3R and MC4R Mechanism

PT-141 acts as an agonist at MC4R and, to a lesser extent, MC3R. MC4R is expressed densely in the paraventricular nucleus of the hypothalamus and other central nervous system regions involved in energy homeostasis, sexual behaviour, and inflammation modulation. MC4R activation by PT-141 in research models produces effects on sexual arousal pathways through a central mechanism distinct from the peripheral vascular mechanism of PDE5 inhibitors. The MC4R pathway is downstream of dopaminergic signalling and is thought to act on desire and arousal initiation rather than on erectile vascular response.

Comparison with Melanotan II

PT-141 and Melanotan II share a common structural origin but differ in their pharmacology. Melanotan II activates MC1R, MC3R, MC4R, and MC5R with significant pigmentation effects. PT-141 removes the MC1R activity and concentrates at the central receptors. Research models that require central melanocortin activation without confounding melanogenic effects typically select PT-141 over Melanotan II for that reason. See the Melanotan I vs Melanotan II comparison for additional context on the melanocortin receptor family.

Research Background

Bremelanotide has received clinical approval in the United States for the treatment of hypoactive sexual desire disorder in pre-menopausal women, under the brand name Vyleesi. This clinical approval applies in the United States and is not extended to the UK. Bremelanotide is not approved for human use in the UK by the MHRA. UK Peptide Lab supplies PT-141 as a research-grade peptide for in-vitro laboratory use only.

Laboratory Handling

PT-141 is supplied as lyophilised powder. Store at -20°C prior to reconstitution. Reconstitute with bacteriostatic water by slowly injecting the diluent down the side of the vial and swirling gently. Never shake. Store reconstituted solutions at 2-8°C and use within 4 weeks. Avoid repeated freeze-thaw cycles.

Sourcing in the UK

UK Peptide Lab supplies research-grade PT-141 10mg with full third-party Certificate of Analysis on every product page. Same-day UK dispatch on orders placed before 2pm GMT, free Royal Mail Tracked shipping over £45. For in-vitro laboratory research use only, not for human consumption.

Originally published at https://ukpeptidelab.co.uk/blog/pt-141-bremelanotide-research-guide. For in-vitro laboratory research only.

TB-500 and BPC-157 are two of the most widely studied peptides in preclinical research. Explore their molecular differences, research applications, and combined laboratory protocols.

Overview

TB-500 and BPC-157 are two of the most widely studied synthetic peptides in preclinical research. Both are frequently examined in the context of tissue repair and inflammatory signalling pathways, and both are commonly used together in laboratory protocols. Despite their overlapping areas of research interest, they are molecularly distinct compounds with different mechanisms and applications.

Researchers can source both BPC-157 and TB-500 from UK Peptide Lab with full batch documentation and UK-based cold chain storage.

Molecular Differences

BPC-157 is a 15 amino acid synthetic peptide derived from a partial sequence of human body protection compound. TB-500 is a synthetic version of Thymosin Beta-4, a naturally occurring 43 amino acid protein found in virtually all human and animal cells. TB-500 specifically corresponds to the actin-binding domain of Thymosin Beta-4, which is understood to be the biologically active region responsible for its effects in cellular research models.

Their molecular weights differ significantly, BPC-157 at approximately 1,419 Da versus TB-500 at approximately 4,963 Da, which influences their behaviour in solution and their interactions with cellular receptors in laboratory models.

Research Applications

BPC-157 research has focused predominantly on gastrointestinal mucosal integrity, tendon and ligament tissue models, angiogenesis, and nitric oxide pathway interactions. It has been examined extensively in rodent models across a wide range of tissue types.

TB-500 research has focused on its role in actin regulation, cell migration, angiogenesis, and inflammation modulation. Thymosin Beta-4 is known to be upregulated in response to tissue injury in biological systems, making TB-500 a useful tool for researchers studying wound healing biology, cardiac tissue models, and neurological repair pathways.

Combined Laboratory Protocols

In laboratory settings, BPC-157 and TB-500 are frequently studied in combination. Their complementary mechanisms, BPC-157's interaction with growth hormone and nitric oxide pathways alongside TB-500's actin regulatory and cell migration properties, make them a commonly used pairing in preclinical tissue research models. Researchers studying repair signalling pathways often use both compounds to examine potential synergistic interactions at the cellular level.

Storage and Handling

Both peptides are supplied as lyophilised powders. Store at -20°C long term and +4°C short term once reconstituted. Reconstitute with bacteriostatic water under sterile conditions. BPC-157 and TB-500 should not be mixed in the same vial unless the research protocol specifically requires it, as this complicates concentration calculations.

Sourcing in the UK

UK Peptide Lab supplies both research-grade BPC-157 and TB-500 as lyophilised powder sourced from GMP certified manufacturers, with batch documentation available. Fast UK delivery via Royal Mail Tracked. Strictly for laboratory and in-vitro research use only.

Originally published at https://ukpeptidelab.co.uk/blog/tb-500-vs-bpc-157-comparison. For in-vitro laboratory research only.

BPC-157 is one of the most widely studied research peptides in preclinical science. Learn about its molecular structure, stability, research applications, and laboratory handling.

What is BPC-157?

BPC-157 (Body Protection Compound-157) is a synthetic pentadecapeptide consisting of 15 amino acids. It is derived from a partial sequence of body protection compound found in human gastric juice. As a stable gastric pentadecapeptide, BPC-157 has become one of the most widely studied research peptides in preclinical science, with a substantial body of literature examining its role in tissue integrity, inflammation signalling, and cellular repair pathways.

For researchers looking to source research-grade BPC-157 in the UK, UK Peptide Lab supplies high-purity BPC-157 with full batch documentation and cold chain storage.

Molecular Structure and Stability

BPC-157 has the amino acid sequence Gly-Glu-Pro-Pro-Pro-Gly-Lys-Pro-Ala-Asp-Asp-Ala-Gly-Leu-Val and a molecular weight of approximately 1,419 Da. One of its most notable characteristics from a research standpoint is its stability, unlike many peptides, BPC-157 remains stable in human gastric juice, which makes it a robust subject for in-vitro and in-vivo research models. It is supplied as a lyophilised white powder and should be reconstituted with bacteriostatic water before use in laboratory settings.

Research Applications

BPC-157 is primarily studied in the context of tissue repair and inflammatory pathway research. Preclinical studies have investigated its interactions with growth hormone receptors, nitric oxide systems, and angiogenic pathways. Research has examined its behaviour in models relating to tendon and ligament tissue, gastrointestinal mucosal integrity, and neurological signalling. It has also been studied alongside growth factors such as VEGF in models exploring wound healing and vascular biology.

In laboratory settings, BPC-157 is frequently used in cell culture models and rodent studies. Researchers studying cytokine expression, fibroblast activity, and collagen synthesis have found it a useful tool for examining repair-related biological pathways.

Many researchers also study BPC-157 in combination with TB-500 to examine potential synergistic effects in tissue repair models. For a detailed comparison of these two peptides, see our TB-500 vs BPC-157 comparison guide.

Laboratory Handling and Storage

BPC-157 should be stored lyophilised at -20°C for long-term stability, with a shelf life of up to 24 months when stored correctly and kept away from light and moisture. Once reconstituted with bacteriostatic water, the solution should be stored at +4°C and used within 4 weeks. Repeated freeze-thaw cycles should be avoided as they can compromise peptide integrity. Always handle under sterile conditions using alcohol-swabbed stoppers and sterile syringes.

Sourcing Research-Grade BPC-157 in the UK

For researchers based in the UK, sourcing verified research-grade BPC-157 from a domestic supplier reduces customs risk and ensures faster, more reliable delivery. UK Peptide Lab supplies research-grade BPC-157 sourced from GMP certified manufacturers, supplied as lyophilised powder with full batch documentation. All products are strictly for in-vitro laboratory research use only.

Originally published at https://ukpeptidelab.co.uk/blog/bpc-157-research-guide. For in-vitro laboratory research only.

CJC-1295 and Ipamorelin are two widely studied growth hormone secretagogues with complementary mechanisms. Learn about their differences, research applications, and why they're often combined in laboratory protocols.

Overview

CJC-1295 and Ipamorelin are two of the most extensively studied growth hormone secretagogues (GHS) in preclinical research. Both stimulate growth hormone release, but they operate through different receptor mechanisms and have distinct pharmacokinetic profiles. Understanding these differences is essential for researchers designing protocols involving growth hormone signalling pathways, particularly those examining combined or synergistic effects.

What is CJC-1295?

CJC-1295 is a synthetic analogue of growth hormone releasing hormone (GHRH). It consists of 29 amino acids and acts as a GHRH receptor agonist, directly stimulating the pituitary gland to produce and release growth hormone. The key characteristic of CJC-1295 is its extended half-life, achieved through a modification that allows it to bind to serum albumin. This results in significantly prolonged activity compared to native GHRH, making it a valuable tool for research examining sustained growth hormone signalling.

CJC-1295 has a molecular weight of approximately 3,367 Da and is available in two forms: with DAC (Drug Affinity Complex) which provides the extended half-life, and without DAC which has a shorter duration of action. Most research-grade CJC-1295 supplied for laboratory use is the DAC form unless otherwise specified.

What is Ipamorelin?

Ipamorelin is a synthetic pentapeptide and selective ghrelin receptor agonist (growth hormone secretagogue receptor, GHS-R). Unlike CJC-1295 which acts on GHRH receptors, Ipamorelin mimics the action of ghrelin, binding to the same receptor to stimulate growth hormone release. It consists of only 5 amino acids, making it a much smaller molecule than CJC-1295, with a molecular weight of approximately 711 Da.

Ipamorelin is notable for its high selectivity, it stimulates growth hormone release without significantly affecting cortisol or prolactin levels in research models, unlike some other ghrelin mimetics such as GHRP-6 or GHRP-2. This selectivity has made it a preferred compound for researchers studying isolated growth hormone signalling pathways.

Receptor Mechanisms: GHRH vs Ghrelin Pathway

The fundamental difference between CJC-1295 and Ipamorelin lies in their receptor targets and mechanisms of action:

CJC-1295 (GHRH pathway): Binds to GHRH receptors on pituitary somatotroph cells, stimulating the synthesis and release of growth hormone through the cAMP signalling cascade. This represents the 'direct' pathway of growth hormone regulation and closely mimics the body's natural GHRH signalling.

Ipamorelin (Ghrelin pathway): Binds to ghrelin receptors (GHS-R1a), stimulating growth hormone release through a distinct mechanism involving calcium and protein kinase C pathways. The ghrelin pathway represents an alternative regulatory mechanism for growth hormone secretion.

Because these two pathways operate through different receptor systems and intracellular signalling cascades, they can have synergistic effects when studied in combination. This receptor complementarity is the basis for combined CJC-1295/Ipamorelin research protocols.

Pharmacokinetics and Duration of Action

CJC-1295 (with DAC) has an extended half-life of approximately 6-8 days in research models due to its albumin-binding modification. This prolonged action allows for less frequent administration in laboratory protocols and provides sustained growth hormone elevation.

Ipamorelin has a much shorter half-life of approximately 2 hours, resulting in a rapid rise and fall in growth hormone levels. This pulsatile pattern more closely resembles natural growth hormone secretion rhythms and may be advantageous in certain research contexts where transient signalling is desired.

The contrasting pharmacokinetics make CJC-1295 and Ipamorelin complementary tools, CJC-1295 provides a sustained baseline elevation, while Ipamorelin produces short-term pulses, together creating a pattern that some researchers hypothesise may more effectively mimic physiological growth hormone dynamics.

Research Applications

Both peptides have been studied extensively in the context of growth hormone biology, metabolic research, body composition models, and tissue repair pathways. Key research areas include:

• Growth hormone secretion dynamics and pulsatility • IGF-1 signalling pathway research • Metabolic regulation and energy expenditure models • Muscle and connective tissue biology • Bone density and skeletal research models • Aging biology and age-related hormone decline • Neuroprotection and cognitive function models

CJC-1295 is particularly valuable in studies requiring sustained growth hormone elevation, while Ipamorelin is preferred when examining acute, pulsatile signalling or when selectivity (minimal cortisol/prolactin effect) is required.

Combined Use in Laboratory Protocols

The combination of CJC-1295 and Ipamorelin is one of the most commonly used pairings in growth hormone research. The rationale is based on their complementary mechanisms:

1. Dual pathway activation: Stimulating both GHRH and ghrelin receptors simultaneously produces greater growth hormone output than either pathway alone in research models.

2. Sustained + pulsatile profile: CJC-1295 provides a sustained baseline, while Ipamorelin adds physiological pulses on top of that baseline.

3. Receptor sensitisation: Some research suggests that alternating between different secretagogue mechanisms may prevent receptor downregulation compared to chronic stimulation of a single pathway.

Typical combined research protocols involve administering both peptides in the same timeframe, though not necessarily in the same injection. Researchers should calculate concentrations separately and maintain sterile handling throughout.

Laboratory Handling and Reconstitution

Both CJC-1295 and Ipamorelin are supplied as lyophilised white powders. Store at -20°C prior to reconstitution. Both should be reconstituted with bacteriostatic water for research applications:

1. Allow vials to reach room temperature

2. Sterilise rubber stoppers with alcohol swabs

3. Slowly inject bacteriostatic water down the inner wall of the vial

4. Gently swirl (never shake) until fully dissolved

5. Store reconstituted solutions at +4°C

6. Use within 4 weeks of reconstitution

For detailed reconstitution guidance, researchers can refer to our complete peptide reconstitution guide or use the free UK Peptide Lab reconstitution calculator.

Sourcing CJC-1295 and Ipamorelin in the UK

UK Peptide Lab supplies research-grade CJC-1295 (with DAC) and Ipamorelin as lyophilised powders sourced from GMP certified manufacturers, with full batch documentation and HPLC verification. Both peptides are available for UK and international delivery via tracked shipping with cold chain storage maintained throughout. All products are strictly for laboratory and in-vitro research use only.

Originally published at https://ukpeptidelab.co.uk/blog/cjc-1295-vs-ipamorelin. For in-vitro laboratory research only.

Cagrilintide is a long-acting amylin analogue developed by Novo Nordisk, central to the REDEFINE clinical programme and co-formulated with semaglutide as CagriSema. Explore the mechanism, research data, and laboratory considerations.

What is Cagrilintide?

Cagrilintide is a long-acting synthetic analogue of human amylin developed by Novo Nordisk as a research compound and clinical candidate in appetite regulation and metabolic disease. It was engineered to overcome the principal limitation of native amylin and earlier analogues such as pramlintide, namely a very short serum half-life that requires multiple daily injections to maintain meaningful exposure. Kruse and colleagues reported on the development of cagrilintide in the Journal of Medicinal Chemistry in 2021, describing it as a stable lipidated amylin analogue selected for once-weekly subcutaneous dosing.

For researchers sourcing the compound in the UK, Cagrilintide is supplied by UK Peptide Lab as research-grade lyophilised powder with third-party HPLC documentation published on the product page.

Amylin and the Receptor Family

Amylin, also known as islet amyloid polypeptide (IAPP), is a 37-amino-acid peptide hormone co-secreted with insulin from pancreatic beta cells in response to meals. It signals through a heterodimeric receptor system formed by the calcitonin receptor in combination with one of three receptor activity-modifying proteins, producing the AMY1, AMY2, and AMY3 receptor subtypes. Activation of these receptors slows gastric emptying, suppresses post-meal glucagon secretion, and engages central satiety pathways through the area postrema in the brainstem.

Native human amylin is highly prone to aggregation into amyloid fibrils, which complicates its use as a research tool. Cagrilintide was designed with sequence modifications and lipidation to resist aggregation while retaining receptor-binding activity, producing a peptide suitable for once-weekly subcutaneous administration in research and clinical models.

Mechanism of Action

Cagrilintide acts as a pan-amylin receptor agonist, binding the AMY1, AMY2, and AMY3 subtypes alongside the calcitonin receptor. Activation produces three pharmacological effects relevant to metabolic research. Slowed gastric emptying extends post-meal nutrient absorption and prolongs satiety signalling. Suppression of post-meal glucagon secretion reduces hepatic glucose output. Central activation of brainstem receptors in the area postrema modulates food intake through pathways distinct from those engaged by GLP-1 receptor agonists.

This mechanistic profile makes cagrilintide complementary to incretin-based research peptides. Where GLP-1 agonists act primarily on hypothalamic appetite circuits, cagrilintide engages brainstem satiety pathways, producing potentially additive effects when the two are studied together.

CagriSema: Cagrilintide and Semaglutide Combined

Cagrilintide is frequently studied in combination with semaglutide, a single-receptor GLP-1 agonist, under the development name CagriSema. The rationale is mechanistic: amylin and GLP-1 receptor agonism engage distinct neural circuits and produce additive effects on energy intake in research models. D'Ascanio and colleagues reviewed the development rationale in Cardiology in Review in 2023, noting that the separate but related mechanisms of an amylin analogue and a GLP-1 receptor agonist appear to produce additive appetite reduction.

For researchers interested in the broader incretin and metabolic peptide field, the Retatrutide triple receptor agonist research guide covers an alternative multi-receptor approach using a single molecule rather than a combination, and the Retatrutide vs Semaglutide research comparison provides context on single vs multi-receptor research peptides.

Phase 2 Research Data

Lau and colleagues published Phase 2 data on cagrilintide monotherapy in The Lancet in 2021. The trial enrolled 706 participants across ten countries and reported dose-dependent weight reductions over 26 weeks, with the highest dose (4.5 mg once-weekly) producing a mean weight reduction of 10.8 percent versus 3.0 percent for placebo. The trial also included an active comparator arm with liraglutide 3.0 mg, against which the highest cagrilintide dose produced numerically greater weight loss.

Frias and colleagues subsequently reported Phase 2 data on the CagriSema combination in The Lancet in 2023. Across 32 weeks in participants with type 2 diabetes, CagriSema produced mean weight loss of 15.6 percent compared with 5.1 percent for semaglutide alone and 8.1 percent for cagrilintide alone, supporting the additive-mechanism hypothesis. Phase 3 trials under the REDEFINE programme are ongoing.

Laboratory Handling

Cagrilintide is supplied as a lyophilised powder. Store at -20°C prior to reconstitution to maintain peptide integrity. Reconstitute with bacteriostatic water by injecting the diluent slowly down the inner wall of the vial and swirling gently. Never shake, as this introduces shear stress and air bubbles that can degrade peptide bonds. Store the reconstituted solution at 2-8°C and use within 4 weeks. Avoid repeated freeze-thaw cycles.

Sourcing in the UK

UK Peptide Lab supplies research-grade Cagrilintide as lyophilised powder sourced from GMP-certified manufacturers, with full third-party HPLC documentation published on the product page. Same-day UK dispatch on orders placed before 2pm GMT, free Royal Mail Tracked shipping over £45. Strictly for in-vitro laboratory research only, not for human consumption.

Originally published at https://ukpeptidelab.co.uk/blog/cagrilintide-amylin-analogue-research-guide. For in-vitro laboratory research only.

GHK-Cu is a naturally occurring copper-binding tripeptide studied for collagen synthesis, ECM biology, and gene expression research. Learn about its molecular properties and laboratory handling.

What is GHK-Cu?

GHK-Cu (Glycine-Histidine-Lysine Copper) is a naturally occurring copper-binding tripeptide found in human plasma, saliva, and urine. First identified by Loren Pickart in 1973, it consists of the tripeptide GHK complexed with a copper (II) ion. Its molecular weight is approximately 340 Da, making it one of the smaller peptides studied in biological research. GHK-Cu has been detected in human plasma at concentrations that decline significantly with age, which has made it an interesting subject for researchers studying ageing biology and extracellular matrix maintenance.

Molecular Properties

The copper ion in GHK-Cu plays a central role in its biological activity in research models. Copper is an essential cofactor for numerous enzymatic processes including lysyl oxidase, which is critical for collagen and elastin crosslinking. GHK-Cu's ability to chelate and transport copper has made it a useful research tool for studying copper-dependent biological processes, metalloproteinase activity, and extracellular matrix remodelling.

Research Applications

GHK-Cu has been studied extensively in the context of collagen synthesis and extracellular matrix biology. In-vitro studies have examined its effects on fibroblast activity, collagen and glycosaminoglycan production, and matrix metalloproteinase regulation. Research has also explored its interactions with growth factors including TGF-beta and VEGF in wound healing models.

In skin biology research, GHK-Cu has been examined for its role in keratinocyte behaviour, dermal fibroblast activity, and angiogenesis. It has also been studied in models relating to anti-inflammatory signalling, nerve tissue, and hair follicle biology.

More recently, research has examined GHK-Cu's potential interactions with gene expression. Studies have suggested it may influence a broad range of genes associated with tissue remodelling, inflammation regulation, and antioxidant defence systems, making it an interesting tool for researchers studying gene regulation in tissue biology contexts.

Laboratory Handling and Storage

GHK-Cu is supplied as a lyophilised powder with a characteristic blue colour due to the copper complex. Store at -20°C long term and away from light. Once reconstituted with bacteriostatic water store at +4°C and use within 4 weeks. Handle under sterile conditions. The blue colouration of the reconstituted solution is normal and expected.

Note that GHK-Cu should be stored separately from other peptides as copper ions can interact with certain compounds. Always use dedicated sterile equipment for each peptide in multi-peptide laboratory protocols.

Sourcing Research-Grade GHK-Cu in the UK

UK Peptide Lab supplies research-grade GHK-Cu copper peptide as lyophilised powder sourced from GMP certified manufacturers, with full batch documentation. Available for fast UK delivery via Royal Mail Tracked. Strictly for in-vitro laboratory research use only.

Originally published at https://ukpeptidelab.co.uk/blog/ghk-cu-copper-peptide-research. For in-vitro laboratory research only.

Retatrutide is a triple receptor agonist peptide developed by Eli Lilly. A complete research guide to its mechanism, current status, and laboratory handling.

What is Retatrutide?

Retatrutide is a synthetic triple receptor agonist peptide developed by Eli Lilly that simultaneously activates the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). It is currently one of the most actively researched compounds in metabolic and incretin biology.

Researchers sourcing the compound in the UK can purchase Retatrutide 10mg, Retatrutide 20mg, or Retatrutide 30mg from UK Peptide Lab with 99.6% HPLC purity and full third-party batch documentation.

Triple-Agonist Mechanism

Retatrutide's defining feature is its simultaneous activity at three distinct metabolic receptors. GLP-1 receptor activation contributes to glucose-dependent insulin secretion and central appetite signalling. GIP receptor agonism modulates both insulin and glucagon secretion in glucose-dependent contexts. Glucagon receptor agonism influences hepatic glucose output and energy expenditure pathways.

The combination of all three mechanisms in a single molecule creates a research tool with no direct precedent, earlier compounds achieved single (Semaglutide) or dual (Tirzepatide) receptor activity but not triple activity in one peptide.

Molecular Properties

Retatrutide has the molecular formula C₂₂₅H₃₄₈N₄₈O₆₈ and a molecular weight of 4767.4 g/mol. It is supplied as lyophilised powder requiring reconstitution with bacteriostatic water before use in laboratory protocols. The compound is stable for up to 24 months at -20°C in lyophilised form, and reconstituted solution should be stored at 2-8°C and used within 4 weeks.

Current Clinical Status

Retatrutide is currently in Phase 3 clinical investigation by Eli Lilly. Phase 2 data published in the New England Journal of Medicine in 2023 reported substantial body weight reductions over 48 weeks across multiple dosing cohorts. It is not approved for human use by any regulatory authority including the MHRA or FDA. All research must be conducted in controlled in-vitro laboratory settings.

Research Applications

Retatrutide is studied across glucose homeostasis, lipid metabolism, energy expenditure, body composition, and appetite regulation models. Its triple mechanism makes it particularly useful for studying receptor crosstalk between incretin and glucagon signalling pathways, a research area that single- or dual-agonist molecules cannot fully address.

The glucagon receptor activity in particular has generated significant research interest because it engages hepatic and thermogenic pathways not activated by GLP-1- or GIP-targeted compounds.

Laboratory Handling and Reconstitution

Allow the Retatrutide vial and bacteriostatic water vial to reach room temperature. Sterilise both stoppers with an alcohol swab. Slowly inject bacteriostatic water down the inner wall of the Retatrutide vial, never directly onto the lyophilised powder, then gently swirl until fully dissolved. Never shake or vortex. Store the reconstituted solution at 2-8°C and use within 4 weeks. See our complete reconstitution guide for protocol details.

Sourcing Retatrutide in the UK

UK Peptide Lab supplies research-grade Retatrutide 10mg, Retatrutide 20mg, and Retatrutide 30mg with 99.6% HPLC purity, batch UKPL-742, third-party tested, with same-day UK dispatch on orders before 2pm GMT and free Royal Mail Tracked shipping over £45. Supplied for in-vitro laboratory research only.

Originally published at https://ukpeptidelab.co.uk/blog/what-is-retatrutide-research-guide. For in-vitro laboratory research only.

Retatrutide is a synthetic peptide and triple receptor agonist that simultaneously targets three receptors, the glucose-dependent insulinotropic polypeptide receptor (GIPR), the glucagon-like peptide-1 receptor (GLP-1R), and the glucagon receptor (GCGR). Developed by Eli Lilly, it represents a significant advancement in incretin-based research compared to earlier dual agonists such as Tirzepatide or single agonists such as Semaglutide. Its unique triple mechanism has made it one of the most actively researched peptides in metabolic science in recent years.

Molecular Mechanism

Retatrutide operates through simultaneous agonism at three distinct receptor pathways. GLP-1 receptor activation is associated with insulin secretion modulation and appetite signalling research. GIPR activation influences insulin and glucagon secretion in glucose-dependent contexts. Glucagon receptor agonism affects hepatic glucose output and energy expenditure pathways. The combination of all three mechanisms in a single peptide makes Retatrutide a uniquely powerful research tool for studying metabolic regulation, energy homeostasis, and receptor crosstalk in laboratory models.

How Retatrutide Differs From Semaglutide and Tirzepatide

Semaglutide is a single GLP-1 receptor agonist. Tirzepatide is a dual GIP/GLP-1 agonist. Retatrutide adds glucagon receptor agonism on top of both, creating a triple mechanism that research suggests produces more pronounced effects on energy expenditure pathways than either predecessor. Phase 2 clinical trial data published in the New England Journal of Medicine in 2023 demonstrated significant findings in metabolic outcomes, generating substantial interest in Retatrutide as a research compound.

Current Research Status

Retatrutide is currently in Phase 3 clinical trials as of 2024. It is not approved for human use by any regulatory body including the MHRA or FDA. All research involving Retatrutide must be conducted in controlled laboratory settings following appropriate ethical and safety guidelines.

Laboratory Handling and Reconstitution

Retatrutide is supplied as a lyophilised powder. Store at -20°C prior to reconstitution. Reconstitute with bacteriostatic water by slowly injecting the diluent down the side of the vial and gently swirling, never shake. Once reconstituted store at +4°C and use within 4 weeks. Handle under sterile conditions throughout.

Sourcing Research Peptides in the UK

UK Peptide Lab supplies research-grade Retatrutide 10mg, Retatrutide 20mg, and Retatrutide 30mg as lyophilised powder sourced from GMP certified manufacturers, with full batch documentation. Available for purchase in the UK with fast Royal Mail tracked delivery. For laboratory and in-vitro research use only. Browse all products.

Originally published at ukpeptidelab.co.uk/blog/retatrutide-triple-receptor-agonist. For in-vitro laboratory research only.

Retatrutide and Semaglutide are two of the most actively researched incretin-based peptides in metabolic science. While both are studied for their effects on glucose homeostasis and body composition, they are pharmacologically distinct molecules. Semaglutide is a single-receptor GLP-1 agonist developed by Novo Nordisk and originally approved for type 2 diabetes. Retatrutide, developed by Eli Lilly and currently in Phase 3 clinical trials, is a triple agonist simultaneously targeting GIP, GLP-1, and glucagon receptors.

For researchers sourcing either compound in the UK, Retatrutide 10mg is supplied at 99.6% HPLC-verified purity with full third-party batch documentation.

Mechanism of Action

Semaglutide acts on a single receptor, the GLP-1 receptor, primarily in pancreatic β-cells, the central nervous system, and the gastrointestinal tract. GLP-1 receptor activation modulates glucose-dependent insulin secretion, slows gastric emptying, and influences appetite via central pathways.

Retatrutide adds two further receptor activities on top of GLP-1: GIP receptor agonism (which influences both insulin and glucagon secretion in glucose-dependent contexts) and glucagon receptor agonism (which affects hepatic glucose output and energy expenditure). The simultaneous activation of all three receptors produces a pharmacological profile that no single- or dual-agonist molecule can replicate, making Retatrutide a uniquely valuable research tool for studying multi-receptor crosstalk.

Phase 2 Clinical Data

Semaglutide's clinical research history is extensive, with multiple Phase 3 trials and regulatory approvals across diabetes and weight management indications. Published data has demonstrated meaningful body weight reductions in trial populations across 68-week treatment periods.

Retatrutide's Phase 2 data, published in the New England Journal of Medicine in 2023, demonstrated body weight reductions over 48 weeks substantially greater than those typically reported for single GLP-1 agonists at comparable timepoints. The triple-receptor mechanism appears to drive amplified energy expenditure through hepatic and thermogenic pathways not engaged by Semaglutide.

Research Applications

Semaglutide is appropriate for researchers studying GLP-1 receptor pharmacology in isolation, particularly in models of pancreatic β-cell function, gastric motility, or central appetite regulation. Retatrutide is the molecule of choice when the research question involves multi-receptor synergy, hepatic glucose handling, or energy expenditure pathways requiring glucagon receptor engagement.

Both peptides are studied in models of insulin sensitivity, lipid metabolism, and metabolic disease, but Retatrutide's broader mechanism makes it particularly suited to research examining receptor crosstalk.

Laboratory Handling

Both peptides are supplied as lyophilised powders requiring reconstitution with bacteriostatic water before use. Store lyophilised vials at -20°C and reconstituted solution at 2-8°C, using within 4 weeks. Inject bacteriostatic water down the inner wall of the vial and swirl gently, never shake. See our reconstitution guide for full protocol.

Sourcing in the UK

UK Peptide Lab supplies research-grade Retatrutide 10mg, Retatrutide 20mg, and Retatrutide 30mg in the UK with third-party HPLC documentation, batch UKPL-742, same-day dispatch on orders before 2pm GMT, and free Royal Mail Tracked shipping over £45. Strictly for in-vitro laboratory research only, not for human consumption.

Originally published at ukpeptidelab.co.uk/blog/retatrutide-vs-semaglutide-research-comparison. For in-vitro laboratory research only.